Evidence map›Paper›PMID 33112988›Full record

ArticleAdvances in biochemical engineering/biotechnology2021

State-of-the-Art Glycomics Technologies in Glycobiotechnology.

Alexander Pralow, Samanta Cajic, Kathirvel Alagesan, Daniel Kolarich, Erdmann Rapp

Open access · greenAbstract read
PubMed Publisher
In one paragraph

Article in Advances in biochemical engineering/biotechnology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
3.5field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Bisecting Lewis X in Hybrid-TypeAnalytical chemistry · 2021
    Article
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Alexander PralowMax Planck Institute for Dynamics of Complex Technical Systems, Magdeburg, Germany.
Samanta CajicMax Planck Institute for Dynamics of Complex Technical Systems, Magdeburg, Germany.
Kathirvel AlagesanInstitute for Glycomics, Griffith University, Gold Coast, QLD, Australia.
Daniel KolarichInstitute for Glycomics, Griffith University, Gold Coast, QLD, Australia.
Erdmann RappMax Planck Institute for Dynamics of Complex Technical Systems, Magdeburg, Germany. rapp@mpi-magdeburg.mpg.de.ORCID https://orcid.org/0000-0001-6618-2626
Max Planck Institute for Dynamics of Complex Technical Systems · DEGriffith University · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glycosylation affects the properties of biologics; thus regulatory bodies classified it as critical quality attribute and force biopharma industry to capture and control it throughout all phases, from R&D till end of product lifetime. The shift from originators to biosimilars further increases importance and extent of glycoanalysis, which thus increases the need for technology platforms enabling reliable high-throughput and in-depth glycan analysis. In this chapter, we will first summarize on established glycoanalytical methods based on liquid chromatography focusing on hydrophilic interaction chromatography, capillary electrophoresis focusing on multiplexed capillary gel electrophoresis, and mass spectrometry focusing on matrix-assisted laser desorption; we will then highlight two emerging technologies based on porous graphitized carbon liquid chromatography and on ion-mobility mass spectrometry as both are highly promising tools to deliver an additional level of information for in-depth glycan analysis; additionally we elaborate on the advantages and challenges of different glycoanalytical technologies and their complementarity; finally, we briefly review applications thereof to biopharmaceutical products. This chapter provides an overview of current state-of-the-art analytical approaches for glycan characterization of biopharmaceuticals that can be employed to capture glycoprotein heterogeneity in a biopharmaceutical context.

Indexed as

Biosimilar PharmaceuticalsGlycomicsGlycosylationMass SpectrometryPolysaccharidesTechnologyBiosimilar PharmaceuticalsPolysaccharidesBiopharmaceuticalsBiosimilarsCapillary electrophoresisGlycomicsGlycoprofileGlycosylationLiquid ChromatographyMass spectrometryVaccines

Identifiers

PMID33112988
OpenAlexW3097242622

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.